Human molecular cytogenetics: diagnosis, prognosis, and disease management.
The year 2001 witnessed the sequencing of 90% of the euchromatic region in the human genome but the ultimate goal to delineate the positions of all genes is yet to be achieved. Fluorescence In Situ Hybridization (FISH) is one of the methods for localizing genes on chromosomes. In the present study, diagnostic utility of single-, dual-, and multicolor FISH was evaluated for prenatal diagnosis, cancer genetics, and screening of various congenital anomalies (sex chromosomal and autosomal). Centromeric probes for chromosomes X and Y were used for screening minor aneuploid cell lines (XXY, XO, and XXX) in the cases of primary amenorrhea and suspected Klinefelter syndrome. The cases with ambiguous genitalia were analyzed using a probe specific for the sex-determining region (SRY). Suspected cases of Down syndrome were subjected to FISH using probe specific for chromosome 21. FISH was also used to study gene alterations in retinoblastoma and myeloid leukemias. Prenatal diagnosis was done to screen for aneuploidies of chromosomes 13, 18, 21, X, and Y using FISH on uncultured cells from amniotic fluid and chorionic villi sampling. The screening for common aneuploidies was extended to abortuses from spontaneous abortions. Using FISH, low-level mosaicism could be identified in some cases of primary amenorrhea and suspected Klinefelter syndrome. Submicroscopic gene rearrangements could be detected using FISH in cases of ambiguous genitalia and cancers. Further interphase FISH could provide results within 24 hours. To conclude, FISH adds to the diagnostic utility of routine cytogenetics and its use on interphase nuclei overcomes the difficulty of conventional cytogenetics, thereby reducing the time between sampling and diagnosis to 24 hr.
Kucheria
Kiran
K
Department of Anatomy, All India Institute of Medical Sciences, New Delhi, India. kkucheria@hotmail.com
Jobanputra
Vaidehi
V
Talwar
Rashmi
R
Ahmad
M E
ME
Dada
Rima
R
Sivakumaran
T A
TA
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002460:Cell Line; D020223:Chromosome Painting; D003581:Cytodiagnosis / Q000379:methods*; D003582:Cytogenetics / Q000379:methods*; D005260:Female; D005820:Genetic Testing; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007231:Infant, Newborn; D016898:Interferon-alpha / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000628:therapy; D008297:Male; D015997:Neonatal Screening; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis; D011296:Prenatal Diagnosis; D011379:Prognosis; D025064:Sex Chromosome Disorders / Q000175:diagnosis / Q000235:genetics
D000970:Antineoplastic Agents; D016898:Interferon-alpha